Cytomx Therapeutics Stock Market Value
| CTMX Stock | USD 0.87 0.02 2.25% |
| Symbol | CytomX |
CytomX Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.819 | Earnings Share 0.16 | Revenue Per Share 1.518 | Quarterly Revenue Growth 0.267 | Return On Assets 0.0233 |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CytomX Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CytomX Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CytomX Therapeutics.
| 12/02/2022 |
| 11/21/2024 |
If you would invest 0.00 in CytomX Therapeutics on December 2, 2022 and sell it all today you would earn a total of 0.00 from holding CytomX Therapeutics or generate 0.0% return on investment in CytomX Therapeutics over 720 days. CytomX Therapeutics is related to or competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, Transcode Therapeutics, and Quoin Pharmaceuticals. CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States More
CytomX Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CytomX Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CytomX Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 20.61 | |||
| Value At Risk | (5.49) | |||
| Potential Upside | 5.0 |
CytomX Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytomX Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CytomX Therapeutics' standard deviation. In reality, there are many statistical measures that can use CytomX Therapeutics historical prices to predict the future CytomX Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.59) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (0.41) |
CytomX Therapeutics Backtested Returns
CytomX Therapeutics secures Sharpe Ratio (or Efficiency) of -0.13, which signifies that the company had a -0.13% return per unit of risk over the last 3 months. CytomX Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CytomX Therapeutics' Mean Deviation of 2.66, risk adjusted performance of (0.09), and Standard Deviation of 3.52 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.18, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CytomX Therapeutics will likely underperform. At this point, CytomX Therapeutics has a negative expected return of -0.46%. Please make sure to confirm CytomX Therapeutics' total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and relative strength index , to decide if CytomX Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.27 |
Poor predictability
CytomX Therapeutics has poor predictability. Overlapping area represents the amount of predictability between CytomX Therapeutics time series from 2nd of December 2022 to 27th of November 2023 and 27th of November 2023 to 21st of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CytomX Therapeutics price movement. The serial correlation of 0.27 indicates that nearly 27.0% of current CytomX Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.27 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.35 |
CytomX Therapeutics lagged returns against current returns
Autocorrelation, which is CytomX Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting CytomX Therapeutics' stock expected returns. We can calculate the autocorrelation of CytomX Therapeutics returns to help us make a trade decision. For example, suppose you find that CytomX Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
CytomX Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If CytomX Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if CytomX Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in CytomX Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
CytomX Therapeutics Lagged Returns
When evaluating CytomX Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of CytomX Therapeutics stock have on its future price. CytomX Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, CytomX Therapeutics autocorrelation shows the relationship between CytomX Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in CytomX Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.